{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:30:39Z","timestamp":1787776239286,"version":"build-2784847793"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>\n                    Postmenopausal women are disproportionately affected by two prevalent chronic conditions: osteoporosis and periodontitis. Bisphosphonates (BPs) are synthetic compounds with a high affinity for bone, widely used for treating postmenopausal osteoporosis due to their ability to inhibit bone resorption, thereby increasing BMD and reducing fracture risk. This systematic review evaluates various bisphosphonate therapies in improving periodontal conditions in postmenopausal women. Fifteen studies involving 776 participants were included. These comprised randomized controlled trials (RCTs), one split-mouth RCT, and one single-group follow-up. BPs studied included zoledronic acid, alendronate, and risedronate, administered via IV, oral, or local delivery. Evaluated parameters included clinical (probing depth [PD], clinical attachment loss [CAL], plaque index [PI], gingival index [GI], bleeding on probing [BOP], sulcus bleeding index [SBI], etc.), radiographic (bone fill, density, height changes), and biochemical\/microbiological (N-terminal telopeptide [NTx], bone-specific alkaline phosphatase, and bacterial counts). Most studies reported significant improvements in PD, CAL, and indices like PI, GI, and BOP. Xu\n                    <jats:italic toggle=\"yes\">et al<\/jats:italic>\n                    . And Bhavsar\n                    <jats:italic toggle=\"yes\">et al<\/jats:italic>\n                    . demonstrated major reductions in PD and CAL. High bone fill percentages and improved alveolar crest height was seen in some studies. Alendronate reduced ntx levels and improved BMD when evaluated under biochemical or microbiological findings. Bacterial counts also decreased post-treatment. Alendronate outperformed atorvastatin and placebo in several studies for periodontal outcomes. Bisphosphonate therapy, in various forms, provides significant benefits in managing periodontitis among postmenopausal women, with improvements noted in clinical, radiographic, and biochemical parameters. Further high-quality research is necessary to optimize treatment protocols and ensure long-term safety.\n                  <\/jats:p>","DOI":"10.4103\/jmh.jmh_120_25","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T19:01:19Z","timestamp":1765220479000},"page":"371-385","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Bisphosphonates and Periodontal Health: A Systematic Review in Postmenopausal Women"],"prefix":"10.4103","volume":"16","author":[{"given":"Meghana","family":"Gangolu","sequence":"first","affiliation":[{"name":"Department of Periodontics, Sibar Institute of Dental Sciences, Guntur, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vintha","family":"Jaswitha","sequence":"additional","affiliation":[{"name":"Department of Periodontics, Sibar Institute of Dental Sciences, Guntur, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramanarayana","family":"Boyapati","sequence":"additional","affiliation":[{"name":"Department of Periodontics, Sibar Institute of Dental Sciences, Guntur, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindranath","family":"Dhulipalla","sequence":"additional","affiliation":[{"name":"Department of Periodontics, Sibar Institute of Dental Sciences, Guntur, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejaswi","family":"Maddukuri","sequence":"additional","affiliation":[{"name":"Department of Periodontics, Trinethra Dental Care, Rajamahendravaram, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Charan","family":"Pasupuleti","sequence":"additional","affiliation":[{"name":"Department of Periodontics, Lenora Institute of Dental Sciences, Rajamahendravaram, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"R1-20251212","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet"},{"key":"R2-20251212","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(05)67728-8","article-title":"Periodontal diseases","volume":"366","author":"Pihlstrom","year":"2005","journal-title":"Lancet"},{"key":"R3-20251212","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates:The first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"R4-20251212","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-20251212","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"R6-20251212","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"R7-20251212","first-page":"S133","article-title":"Bisphosphonates in periodontal therapy","volume":"89","author":"Reddy","year":"2018","journal-title":"J Periodontol."},{"key":"R8-20251212","first-page":"411","article-title":"Effectiveness of bisphosphonates in the treatment of periodontitis:A systematic review","volume":"48","author":"Sgolastra","year":"2013","journal-title":"J Periodontal Res"},{"key":"R9-20251212","first-page":"251","article-title":"Bisphosphonate therapy and periodontal disease:A review of the literature","volume":"42","author":"Lane","year":"2015","journal-title":"J Clin Periodontol"},{"key":"R10-20251212","first-page":"13","article-title":"The role of bisphosphonates in periodontal therapy","volume":"88","author":"Jeffcoat","year":"2017","journal-title":"J Periodontol"},{"key":"R11-20251212","first-page":"1419","article-title":"Bisphosphonate use and periodontal disease in postmenopausal women:A systematic review","volume":"26","author":"Coslet","year":"2019","journal-title":"Menopause"},{"key":"R12-20251212","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R13-20251212","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/0972-124X.65438","article-title":"Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects","volume":"14","author":"Veena","year":"2010","journal-title":"J Indian Soc Periodontol"},{"key":"R14-20251212","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s00198-016-3577-8","article-title":"Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women (12-month study)","volume":"27","author":"Bhavsar","year":"2016","journal-title":"Osteoporos Int"},{"key":"R15-20251212","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1902\/jop.2011.110206","article-title":"Clinical efficacy of 1% alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis:A randomized controlled clinical trial","volume":"83","author":"Sharma","year":"2012","journal-title":"J Periodontol"},{"key":"R16-20251212","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.62347\/GXEB5902","article-title":"Zoledronic acid improves periodontal health, reduces serum inflammation, and enhances bone metabolism in postmenopausal osteoporosis complicated by periodontitis","volume":"16","author":"Xu","year":"2024","journal-title":"Am J Transl Res"},{"key":"R17-20251212","first-page":"795","article-title":"Analysis of the efficacy of zoledronic acid in patients with osteoporosis combined with periodontitis in menopause","volume":"20","author":"Zhang","year":"2016","journal-title":"Anhui Med Pharm J"},{"key":"R18-20251212","first-page":"100","article-title":"Analysis of the effect of zoledronic acid in the treatment of postmenopausal osteoporosis combined with periodontitis","volume":"41","author":"Zhang","year":"2021","journal-title":"Clin Med"},{"key":"R19-20251212","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.4103\/jfmpc.jfmpc_724_20","article-title":"Clinical efficacy of amino bisphosphonate on periodontal disease status in postmenopausal women:Randomized double-blind placebo-controlled trial","volume":"9","author":"Gupta","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"R20-20251212","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1902\/jop.2005.76.7.1113","article-title":"Bisphosphonate therapy improves the outcome of conventional periodontal treatment:Results of a 12-month, randomized, placebo-controlled study","volume":"76","author":"Lane","year":"2005","journal-title":"J Periodontol"},{"key":"R21-20251212","first-page":"66","article-title":"Role of alendronate gel versus chlorhexidine gel as adjunct to mechanical therapy in treatment of chronic periodontitis (clinical and microbiological study)","volume":"9","author":"El-Hadidy","year":"2022","journal-title":"Mans J Dent"},{"key":"R22-20251212","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1902\/jop.2012.110292","article-title":"Local drug delivery of alendronate gel for the treatment of patients with chronic periodontitis with diabetes mellitus:A double-masked controlled clinical trial","volume":"83","author":"Pradeep","year":"2012","journal-title":"J Periodontol"},{"key":"R23-20251212","doi-asserted-by":"crossref","DOI":"10.1111\/jicd.12215","article-title":"Comparative evaluation of subgingivally delivered 1% alendronate versus 1.2% atorvastatin gel in treatment of chronic periodontitis:A randomized placebo-controlled clinical trial","volume":"8","author":"Pradeep","year":"2017","journal-title":"J Investig Clin Dent"},{"key":"R24-20251212","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1902\/jop.2012.110729","article-title":"1% alendronate gel as local drug delivery in the treatment of class II furcation defects:A randomized controlled clinical trial","volume":"84","author":"Pradeep","year":"2013","journal-title":"J Periodontol"},{"key":"R25-20251212","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1902\/jop.2001.72.2.204","article-title":"Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate:A randomized, placebo-controlled trial","volume":"72","author":"Rocha","year":"2001","journal-title":"J Periodontol"},{"key":"R26-20251212","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1902\/jop.2004.75.12.1579","article-title":"Effect of alendronate on periodontal disease in postmenopausal women:A randomized placebo-controlled trial","volume":"75","author":"Rocha","year":"2004","journal-title":"J Periodontol"},{"key":"R27-20251212","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1902\/jop.2011.110091","article-title":"Clinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis:A randomized, controlled clinical trial","volume":"83","author":"Sharma","year":"2012","journal-title":"J Periodontol"},{"key":"R28-20251212","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1172\/JCI114100","article-title":"Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow","volume":"83","author":"Hughes","year":"1989","journal-title":"J Clin Invest"},{"key":"R29-20251212","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1210\/endo.137.6.8641182","article-title":"Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption","volume":"137","author":"Vitt\u00e9","year":"1996","journal-title":"Endocrinology"},{"key":"R30-20251212","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jmbbm.2013.08.029","article-title":"Effects of ageing, prolonged estrogen deficiency and zoledronate on bone tissue mineral distribution","volume":"29","author":"Brennan","year":"2014","journal-title":"J Mech Behav Biomed Mater"},{"key":"R31-20251212","first-page":"5","article-title":"The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial)","volume":"5","author":"El-Shinnawi","year":"2003","journal-title":"J Int Acad Periodontol"},{"issue":"Suppl 22","key":"R32-20251212","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/jcpe.13232","article-title":"The adjunctive use of host modulators in non-surgical periodontal therapy. A systematic review of randomized, placebo-controlled clinical studies","volume":"47","author":"Donos","year":"2020","journal-title":"J Clin Periodontol"},{"key":"R33-20251212","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/prd.12315","article-title":"Periodontal therapeutics:Current host-modulation agents and future directions","volume":"82","author":"Golub","year":"2020","journal-title":"Periodontol 2000"},{"key":"R34-20251212","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0169-6009(08)80254-1","article-title":"Ceramic hydroxyapatite implants for the release of bisphosphonate","volume":"25","author":"Denissen","year":"1994","journal-title":"Bone Miner"},{"key":"R35-20251212","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-0765.1997.tb01380.x","article-title":"Net-shaped hydroxyapatite implants for release of agents modulating periodontal-like tissues","volume":"32","author":"Denissen","year":"1997","journal-title":"J Periodontal Res"},{"key":"R36-20251212","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.biomaterials.2004.05.019","article-title":"Novel biomaterials for bisphosphonate delivery","volume":"26","author":"Josse","year":"2005","journal-title":"Biomaterials"},{"key":"R37-20251212","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1359-6446(04)03318-5","article-title":"Calcium phosphate biomaterial for the delivery of anti-osteoporotic drugs","volume":"10","author":"Guicheux","year":"2005","journal-title":"Drug Discov Today"},{"key":"R38-20251212","first-page":"3","article-title":"Bisphosphonates in periodontal treatment:A review","volume":"7","author":"Badran","year":"2009","journal-title":"Oral Health Prev Dent"},{"key":"R39-20251212","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1677\/joe.0.1700451","article-title":"Changing RANKL\/OPG mRNA expression in differentiating murine primary osteoblasts","volume":"170","author":"Thomas","year":"2001","journal-title":"J Endocrinol"},{"key":"R40-20251212","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R41-20251212","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)","volume":"19","author":"Pan","year":"2004","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Mid-life Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jmh.jmh_120_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:01:42Z","timestamp":1787774502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jmh.jmh_120_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jmh.jmh_120_25","relation":{},"ISSN":["0976-7800","0976-7819"],"issn-type":[{"value":"0976-7800","type":"print"},{"value":"0976-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-05-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}